<DOC>
	<DOCNO>NCT01447225</DOCNO>
	<brief_summary>To evaluate safety tolerability escalate dos MM-121 + certain anticancer therapy</brief_summary>
	<brief_title>Safety Study MM-121 Combination With Multiple Anticancer Therapies Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This study Phase 1 pharmacologic dose-escalation trial MM-121 combination certain anticancer therapy . The dose-escalation portion study employ 3 + 3 design ass safety , tolerability , pharmacokinetics MM-121 administer weekly combination certain anticancer therapy patient advanced/recurrent cancer . Doses MM-121 and/or anticancer therapy escalate either MTD identify combination show tolerable high planned dos .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Advancedstage solid tumor â‰¥ 18 year age Adequate liver kidney function Any active malignancy No known HIV , Hepatitis C B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Advanced-stage</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>MM-121</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Cabazitaxel</keyword>
	<keyword>ErbB3</keyword>
	<keyword>Phase I</keyword>
	<keyword>Cancer</keyword>
</DOC>